Key Takeaways

Key players operating in the Metabolism Drugs Market are 3M, Automotive Technology Products LLC, Caliber Collision Centers, Continental AG, Denso Corporation, DRiV Incorporated, Faurecia, Gerber Collision & Glass, Honeywell International, Inc., International Automotive Components Group, Johnson Controls Inc., Magna International, Inc., Mann+Hummel Group, Martinrea International, Inc., Mitsuba Corporation, Robert Bosch GmbH, and ZF Friedrichshafen AG.

The global demand for metabolism drugs is increasing owing to rise in sedentary lifestyles and consumption of junk food. According to the WHO, worldwide obesity has nearly tripled since 1975 and in 2016, around 39% of adults aged 18 years and over were overweight. Obesity decreases life expectancy and increases the lifelong risks of cardiovascular diseases, diabetes, musculoskeletal disorders and certain cancers. Thus, increasing obesity rates are expected to drive the demand for metabolism drugs over the forecast period.

Geographically, North America dominates the global metabolism drugs market owing to increasing healthcare investments and growing geriatric population with diabetes. However, Asia Pacific market is expected to grow at a higher CAGR during the forecast period with rising medical tourism in low cost countries and rapid economic growth in China and India. Market players are focusing on expanding their manufacturing and distribution networks in developing regions to tap the growth opportunities.

The key drivers of Metabolism Drugs Market include rising sedentary lifestyles and junk food consumption leading to growing obesity rates globally. Lack of physical activity and consumption of calorie-dense processed foods high in fat, sugar and salt promotes weight gain and diabetes. Long working hours and dependence on automobiles for mobility has reduced physical exertion in daily lives. This unhealthy lifestyle is a major factor behind the obesity pandemic which in turn drives the need for metabolism drugs to manage weight-related chronic metabolic conditions.

Geographical Regions Where the Market is Concentrated
The Metabolism Drugs Market Demand  in terms of value is highly concentrated in North America and Europe. North America currently dominates the global metabolism drugs market, primarily due to the rising prevalence of obesity and diabetes in the United States. According to Centers for Disease Control and Prevention (CDC), over 93.3 million American adults are diagnosed with obesity. The increasing awareness about diseases like diabetes and obesity and availability of advanced drugs to treat these conditions are fueling the growth of metabolism drugs market in North America. Europe is the second largest regional market for metabolism drugs. The high adoption of novel medications and growing obese population are some key factors boosting the metabolism drugs sales in major European countries like Germany, United Kingdom, France, Italy, and Spain.

Fastest Growing Region for the Metabolism Drugs Market
Asia Pacific region is expected to witness the highest growth in the global metabolism drugs market during the forecast period. Factors such as rising living standards, growing health consciousness, increasing obese population, and rapid economic development are driving the demand for metabolism drugs in Asia Pacific. According to the World Health Organization (WHO), nearly 60% of the world's obese population lives in Asia. Countries like China, India, Japan, and South Korea are emerging as highly lucrative markets for metabolism drugs due to surging prevalence of lifestyle diseases. Furthermore, presence of prominent generic drug manufacturers and rising healthcare expenditures are positively impacting the growth of metabolism drugs market in Asia Pacific.

Explore more information on this topic, Please visit-   
https://www.pressreleasebulletin.com/metabolism-drugs-market-size-and-share-analysis-growth-trends-and-forecasts/